Calidi Biotherapeutics Facing NYSE Delisting Risk Over Equity Deficiency — Calidi Biotherapeutics, Inc.

Event summary

Calidi Biotherapeutics received a notification from NYSE American on September 21, 2026, for failing to meet the stockholders' equity requirement of $4.0 million.
The company must submit a compliance plan by October 21, 2026, to regain compliance by March 21, 2028.
Failure to submit or gain acceptance of the plan could lead to delisting proceedings.
The company's stock will continue to trade with a '.BC' designation indicating 'below compliance'.
Calidi's lead candidate, CLD-401, is currently in IND-enabling studies for metastatic non-small cell lung cancer and other tumor types.

The big picture

Calidi Biotherapeutics' equity deficiency highlights the financial pressures facing early-stage biotech companies with high research and development costs. The situation underscores the importance of maintaining sufficient market capitalization to meet exchange listing standards, particularly for firms reliant on investor confidence and clinical trial success to drive valuation. The company's ability to navigate this regulatory challenge will be critical in determining its long-term viability in the competitive biotech landscape.

What we're watching

Financial Recovery: Whether Calidi can raise sufficient capital to increase stockholders’ equity and avoid delisting.
Regulatory Compliance: The pace at which Calidi can submit and gain acceptance of a compliance plan by the NYSE American.
Clinical Progress: How the company's ongoing clinical trials and pipeline advancements will impact its financial stability and market position.